China Tiotropium Bromide Market Report 2015-2019

News provided by

Sep 03, 2015, 09:10 ET

DUBLIN, Sep. 03, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/rvchgj/investigation) has announced the addition of the "Investigation Report on China Tiotropium Bromide Market, 2010-2019" report to their offering.

According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003- 2033.

For many years, the COPD market and anti- asthmatic agents market have been dominated by four big companies - GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.

Tiotropium bromide, a long- acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD's clinical course so as to help improve the state of patient's life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.

According to CRI's survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006- 2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.

Key Topics Covered:

1 Related Concepts of Tiotropium Bromide

2 Market Profile of Tiotropium Bromide in China

3 Survey on Sales Status of Tiotropium Bromide in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Tiotropium Bromide in China, 2010-2014

5 Survey on Dosage Forms of Tiotropium Bromide in China, 2010-2014

6 Reference Price of Tiotropium Bromide in Chinese Hospitals in 2014

7 Major Manufacturers of Tiotropium Bromide in Chinese Market, 2010-2014

8 Market Outlook of Tiotropium Bromide in China, 2015-2019

Companies Mentioned

- Boehringer Ingelheim (Germany)
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd
- Zhejiang Xianju Pharmaceutical Co., Ltd

For more information visit http://www.researchandmarkets.com/research/rvchgj/investigation